Hepatocellular Adenoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Overall, while chronic administration of the model CAR activator NaPB results in both hepatocellular adenoma and carcinoma in the low spontaneous liver tumour incidence C57BL/10 J mouse strain, only 40% of the liver tumours evaluated in this study had β-catenin mutations.
|
31836555 |
2020 |
Hepatocellular Adenoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Meanwhile, β-catenin mutated hepatocellular adenoma patients with malignant transformation were predominantly male (67%, p = 0.018) with single lesion (86%, p = 0.0009).
|
31570768 |
2019 |
Hepatocellular Adenoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
All six hepatocellular adenomas with malignancy were β-catenin activated; β-catenin activation could serve as a biomarker for malignant progression.
|
31698521 |
2019 |
Hepatocellular Adenoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The mutational status of the <i>CTNNB1</i> gene was determined in ß-catenin-activated HCA (b-HCA) and HCC with at least moderate nuclear CTNNB1 accumulation.
|
30901310 |
2019 |
Hepatocellular Adenoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
HCA were classified as inflammatory (n = 6), steatotic (n = 4), or β-catenin activated (n = 1) subtypes.
|
30052636 |
2018 |
Hepatocellular Adenoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Focal β-catenin mutation identified on formalin-fixed and paraffin-embedded inflammatory hepatocellular adenomas.
|
28618047 |
2017 |
Hepatocellular Adenoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Liver fatty acid-binding protein, serum amyloid A, C-reactive protein, prostaglandin D2 synthetase, GS, and β-catenin can be used either on biopsy or surgical specimen to classify hepatocellular adenoma into hepatocyte nuclear factor (HNF-1α) inactivated (steatotic), inflammatory, with dysregulation of sonic hedgehog and prostaglandin pathways, β-catenin mutated, and unclassified.
|
28280721 |
2017 |
Hepatocellular Adenoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression in HA was variable and differed between molecular subtypes of this neoplasm: inflammatory and HNF1A mutation-associated type are characterized by overexpression of c-MET to an extent comparable with poorly-differentiated HCC, whereas Wnt/β-catenin dysfunction-associated type lacks overexpression, and the amount of c-MET protein accumulated in its cells is similar to the levels in non-neoplastic tissue and well- to moderately-differentiated HCC.
|
29256857 |
2017 |
Hepatocellular Adenoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
HAs presented as a heterogeneous group, with loss of PTEN observed in the inflammatory and HNF1A-mutated subtype and relatively intact PTEN expression in HA with nuclear β-catenin overexpression.
|
29687774 |
2017 |
Hepatocellular Adenoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Specific molecular subgroup of HCA with β-catenin and sonic hedgehog activation associated with malignant transformation and bleeding, respectively.
|
27939373 |
2017 |
Hepatocellular Adenoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This single entity has been split into 3 subtypes corresponding to specific mutations: HNF1α-inactivated HCA; inflammatory HCA related to different mutations, all leading to activation of STAT3 pathway; and β-catenin-activated HCA related to CTNNB1 mutations.
|
28506364 |
2017 |
Hepatocellular Adenoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CTNNB1 mutated HCA in exon 3 and sonic hedgehog HCA have been linked with a high risk of malignant transformation and bleeding respectively.
|
28733222 |
2017 |
Hepatocellular Adenoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In HCA, CTNNB1 mutations predispose to transformation of HCA in HCC and TERT promoter mutations are required in most of the cases as a second hit for a full malignant transformation.
|
26336998 |
2016 |
Hepatocellular Adenoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The results show a modest correlation between diffuse glutamine synthetase immunostaining and exon 3 β-catenin mutations in hepatocellular adenoma and hepatocellular carcinoma with discrepancy rates >50% in both hepatocellular adenoma and hepatocellular carcinoma.
|
27469330 |
2016 |
Hepatocellular Adenoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
All 36 sequenced HCAs showed HNF1α mutations (72% missense, 28% synonymous), 2 hotspot polymorphisms of HNF1α (I27L: rs1169288 and S487N: rs2464196) were seen in 17 (47%) and 10 (27.8%) cases, respectively, and a novel single nucleotide polymorphism site (rs1169304) in intron 9 of HNF1α was detected in 32 (88%) cases, but no β-catenin or gp130 gene mutation was detected, and no nuclear β-catenin staining was detected by immunohistochemistry.
|
26608415 |
2015 |
Hepatocellular Adenoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Hepatocellular adenomas (HCAs) are heterogeneous group of benign tumors; three pathomolecular subtypes have been identified so far: hepatocyte nuclear factor 1 α-inactivated HCA (H-HCA) (35-40%), inflammatory HCA (I-HCA) (>50%), β-catenin activated HCA (10%).
|
25260568 |
2015 |
Hepatocellular Adenoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Genotype-phenotype classification of the pigmented tumors showed different subtypes: HNF1α inactivated (48%), β-catenin activated (26%), inflammatory (15%), concurrently β-catenin activated and inflammatory in 1 hepatocellular adenoma, concurrently HNF-1α inactivated and β-catenin activated in 1 hepatocellular adenoma, and unclassified in 1 hepatocellular carcinoma.
|
26205181 |
2015 |
Hepatocellular Adenoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
β-catenin activating HCA has increased activity of the Wnt/β-catenin pathway and is associated with possible malignant transformation.
|
25195525 |
2015 |
Hepatocellular Adenoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, the hepatocellular adenoma-like portion of most cases of hepatocellular carcinoma arising in hepatocellular adenoma shows features typically seen in hepatocellular carcinoma such as focal morphological abnormalities, β-catenin activation, heat-shock protein 70 expression, and chromosomal gains.
|
24743216 |
2014 |
Hepatocellular Adenoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We also observed higher ALDH3A1 expression in CTNNB1-mutated HCA when compared with other subtypes.
|
24276407 |
2014 |
Hepatocellular Adenoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We report a case of a peliotic adenoma that was morphologically consistent with a β-catenin wild-type hepatocellular adenoma but harbored a β-catenin mutation by molecular analysis.
|
24997695 |
2014 |
Hepatocellular Adenoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Finally, integrative analysis of HCAs transformed to hepatocellular carcinoma revealed β-catenin mutation as an early alteration and TERT promoter mutations as associated with the last step of the adenoma-carcinoma transition.
|
24735922 |
2014 |
Hepatocellular Adenoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hepatocellular adenomas (HCA) are benign liver tumors mainly related to oral contraception and classified into 4 molecular subgroups: inflammatory (IHCA), HNF1A-inactivated (H-HCA), β-catenin-activated (bHCA) or unclassified (UHCA).
|
23046672 |
2013 |
Hepatocellular Adenoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Atypical hepatocellular adenoma-like neoplasms with β-catenin activation show cytogenetic alterations similar to well-differentiated hepatocellular carcinomas.
|
23084586 |
2013 |
Hepatocellular Adenoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Gene expression and mutation assessment provide clues of genetic and epigenetic mechanisms in liver tumors of oxazepam-exposed mice.
|
21147764 |
2011 |